Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy

• Verfasst von: Wasem, Jürgen [VerfasserIn]
• Verfasst von: Bramlage, Peter [VerfasserIn]
• Verfasst von: Gitt, Anselm Kai [VerfasserIn]
• Verfasst von: Binz, Christiane [VerfasserIn]
• Verfasst von: Krekler, Michael [VerfasserIn]
• Verfasst von: Deeg, Evelin [VerfasserIn]
• Verfasst von: Tschöpe, Diethelm [VerfasserIn]
• Titel: Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy
• Titelzusatz: an analysis of the DiaRegis registry
• Verf.angabe: Jürgen Wasem, Peter Bramlage, Anselm K. Gitt, Christiane Binz, Michael Krekler, Evelin Deeg, Diethelm Tschöpe, for the DiaRegis Study Group
• E-Jahr: 2013
• Jahr: 20 March 2013
• Umfang: 8 S.
• Teil: volume:12
• Teil: year:2013
• Teil: elocationid:47
• Teil: pages:1-8
• Teil: extent:8
• Fussnoten: Gesehen am 30.09.2021
• Titel Quelle: Enthalten in: Cardiovascular diabetology
• Ort Quelle: London : BioMed Central, 2002
• Jahr Quelle: 2013
• Band/Heft Quelle: 12(2013), Artikel-ID 47, Seite 1-8
• ISSN Quelle: 1475-2840
• DOI: doi:10.1186/1475-2840-12-47
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Glipizide
• Sach-SW: Glycaemic Control
• Sach-SW: Metformin
• Sach-SW: Minimal Important Difference
• Sach-SW: Peripheral Artery Disease
• K10plus-PPN: 1772152722

Abstract

Background: Type-2 diabetes mellitus has a major impact on health related quality of life (HRQoL). We aimed to identify patient and treatment related variables having a major impact. Methods: DiaRegis is a prospective diabetes registry. The EQ-5D was used to describe differences in HRQoL at baseline. Odds ratios (OR) with 95% confidence intervals (CI) were determined from univariable regression analysis. For the identification of independent predictors of a low score on the EQ-5D, multivariable unconditional logistic regression analysis was performed. Results: A total of 2,760 patients were available for the present analysis (46.7% female, median age 66.2 years). Patients had considerable co-morbidity (18.3% coronary artery disease, 10.6% heart failure, 5.9% PAD and 5.0% stroke/TIA). Baseline HbA1c was 7.4%, fasting- and postprandial plasma glucose 139 mg/dl and 183 mg/dl. The median EQ-5D was 0.9 (interquartile range [IQR] 0.8–1.0). Independent predictors for a low EQ-5D were age > 66 years (OR 1.49; 95%CI 1.08–2.06), female gender (2.11; 1.55–2.86), hypertension (1.73; 1.03–2.93), peripheral neuropathy (1.62; 0.93–2.84) and clinically relevant depression (11.01; 3.97–30.50). There was no influence of dysglycaemia on the EQ-5D score. Conclusion: The present study suggests, that co-morbidity but not average glycaemic control reduces health related quality of life in type 2 diabetes mellitus.